Selskabets formål er: at etablere, at erhverve og at finansiere, at deltage i og udføre management i andre virksomheder, at handle med produkter indenfor fødevare-, sundheds- og miljøområdet, at udvikle og/eller at producere sådanne produkter, alt i videste forstand, at erhverve og afhænde immaterialrettigheder og at udøve enhver handling, som er knyttet til eller er en konsekvens af det foranstående i videst muligt omfang.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 191 mio. | 5.7 mio. | 110 mio. | 20.8 mio. | 96 | |
CVR: 10888638
Secondary names: BROCADES PHARMA A/S, ASTELLAS A/S, YAMANOUCHI PHARMA A/S
Mark Andree Dekker joined the board
Morten Auscher left the board
Mark Andree Dekker joined as director
Morten Auscher left as ADM. DIR.
Companies in the same industry and area
CVR 33671245
CVR 40041796
CVR 40549676
CVR 40557806
CVR 43707795
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Astellas Pharma A/S demonstrates a stable financial health with a positive revenue trend, increasing from 160.5 million DKK in 2021 to 191.0 million DKK in 2025. Profitability has also improved, with profits rising from 2.1 million DKK in 2023 to 5.7 million DKK in 2025, although there was a notable dip in 2022. The company's equity has decreased significantly from 58.2 million DKK in 2022 to 20.8 million DKK in 2025, raising concerns about its long-term financial stability. Positioned within the pharmaceutical wholesale industry, Astellas Pharma A/S is navigating a competitive landscape while maintaining a focus on growth.
AI-generated summary
companydata.dk